Fierce Pharma Asia—Daiichi's leukemia nod; Astellas' protein degrader pact; Takeda's neuroscience setback

Preview

来源: FiercePharma

The FDA approval for Daiichi Sankyo's Vanflyta, a protein degrader deal between Astellas and PeptiDream, and a Takeda trial flop made our news this week.

Daiichi Sankyo's FLT3 inhibitorFLT3 inhibitor overcame FDA rejection to win an approval. Astellas signed another protein degrader deal, this time with PeptiDream. Takeda's enzyme replacement therapy flunked a mid-stage trial in a rare neurological disorder. And more.

1. After FDA snub, Daiichi's Vanflyta gains US approval and tees up AMLAML clash with Novartis, Astellas

About four years after an initial FDA rejection, Daiichi Sankyo has finally won approval for its FLT3 inhibitorFLT3 inhibitor quizatinib as a treatment for acute myeloid leukemia. Now marketed as Vanflyta, the Daiichi drug will compete against Astellas’ Xospata and Novartis’ Rydapt. Vanflyta’s label only covers cancers with FLT3-ITD mutations, while its rivals' approvals cover any FLT3 mutations.

2. Astellas notches another protein degrader pact with $21M upfront for PeptiDream

Astellas has put down 3 billion yen ($21 million) up front to tap PeptiDream’s peptide discovery platform to develop protein degraders. PeptiDream will also be in line for potential milestone payments up to 20.6 billion yen ($145 million) per target, plus single-digit percentage sales royalties. Astellas has previously inked protein degrader deals with Cullgen and Fimecs.

3. Takeda suffers setback as promising neuroscience prospect flunks phase 2

Takeda’s TAK-611, an enzyme replacement therapy proposed for the rare genetic disease metachromatic leukodystrophy, has failed in a mid-stage trial. The phase 2 trial didn’t meet primary or secondary endpoints, according to Takeda. The readout was listed as a potential inflection point for Takeda’s late-stage neuroscience programs for this fiscal year.

4. Takeda hypes up dengue vaccine launch progress as Vyvanse generics loom

Takeda is touting the progress of its dengue vaccine Qdenga despite a recent decision to pull its application in the U.S. The company is now focused on some endemic markets, which make up about 80% to 85% of the vaccine’s peak sales projection of $1.6 billion to $2 billion, CEO Christophe Weber said on a confererence call. Takeda is getting closer to having end-to-end in-house production capability for Qdenga by 2025, he said.

5. Lawmakers propose federal database to track supply chain vulnerabilities

Sen. Gary Peters (D-MI), chair of the Homeland Security and Governmental Affairs Committee, has teamed with Republican Sens. James Lankford (R-OK) and Mike Braun (R-IN) to introduce a bill to create a federal database to track supply chain vulnerabilities. The Mapping America’s Pharmaceutical Supply Act would catalog the origin of each drug, quantities available and the location of their manufacturing facilities.

6. Centaur Pharmaceuticals slapped with FDA warning letter outlining quality, cleaning lapses

Centaur Pharmaceuticals’ drug ingredient plant in Maharashtra, India, got an FDA warning letter with two observations about quality deficiencies and lapses in cleaning protocols. The agency is demanding Centaur completely assess its documentation systems and manufacturing standards training program.

Other News of Note

7. AstraZeneca enlists SK Chemicals to produce diabetes combo drug Sidapvia

8. India’s pharma exports continue to rise despite manufacturing scandals, trade body says (Reuters)

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。